Biocon pharmaceuticals, one of India’s pharmaceutical major has reported 3% less profits at Rs.97.8 crore for Q4 of FY 2012 which ended on March 31st; main reason being zero licensing income during this quarter.

Biocon

Company’s revenues though showed a positive trend with an increase by 25% in the quarter to Rs.611.5 crore from Rs.487.9 crore during the same period of last fiscal year. Positive news is that branded formulations by the company rose by 34% and contract research performed increased by 33%!

For the entire FY 2011-12, company’s’ profit took a beat of 8% and stood at Rs.338.4 crore against Rs.367.5 crore last year. Overall revenues for the year were up by 16% and were at Rs.2148.3 crore compared to Rs.1857.9 crore during last fiscal.